Table 2.
Ongoing Clinical Trials with Regorafenib and PD-1/PD-L1 Inhibitors in Hepatocellular Carcinoma
| NCT Number | Study Title | N | Interventions | Trial Phase | Primary Endpoint | Current Status |
|---|---|---|---|---|---|---|
| NCT 04170556 |
Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma | 60 | Regorafenib+ Nivolumab | 1 and 2 | AE TTP |
Recruiting |
| NCT 04183088 |
Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma | 125 | Regorafenib+ Tislelizumab |
2 | AE ORR |
Not yet recruiting |
| NCT 03347292 |
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | 57 | Regorafenib+ Pembrolizumab |
1 | AE | Recruiting |
| NCT 03475953 |
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors | 362 | Regorafenib+ Avelumab |
1 and 2 | Phase 1: Recommended phase 2 Dose Phase 2: Assessment of the antitumor activity of regorafenib |
Recruiting |
| NCT 04310709 |
Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma | 42 | Regorafenib+ Nivolumab |
2 | RR | Not yet recruiting |
Abbreviations: AE, adverse events; TTP, time to progression; ORR, objective response rate; RR, response rate.